Moderate

Rheumatoid arthritis (RA) — chronic management & DMARD therapy (seropositive/seronegative; distinct from acute complications)

Rheumatoid arthritis · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic symmetrical inflammatory polyarthritis of small joints (MCP, PIP, wrists, MTP) with synovitis, morning stiffness >30-60 min, RF/anti-CCP positivity (seropositive ~70%) and radiographic erosions. Untreated it causes joint destruction, deformity (ulnar deviation, swan-neck, boutonniere) and excess cardiovascular/lymphoma risk. Core principle = treat-to-target: start conventional synthetic DMARD (csDMARD) early within the 'window of opportunity', aim for remission or low disease activity (DAS28/CDAI), escalate every 3 months until target met. Methotrexate is the anchor drug. This entry is outpatient/initiation management, NOT the acute-complications entry.

Red flags

  • Fever + hot swollen joint on immunosuppression — exclude SEPTIC ARTHRITIS (aspirate before assuming flare)
  • New neck pain, limb paraesthesia, gait disturbance — atlanto-axial subluxation / cervical myelopathy (image before intubation/GA)
  • Breathlessness/cough on methotrexate — MTX pneumonitis or RA-ILD; stop MTX, investigate
  • Febrile neutropenia / sepsis on DMARD or biologic — hold immunosuppression, treat as neutropenic sepsis
  • Mononeuritis multiplex, skin ulcers, serositis — rheumatoid vasculitis (severe seropositive disease)

Assessment

Differential diagnosis

  • Psoriatic arthritis (DIP involvement, dactylitis, nail/skin psoriasis, RF-negative)
  • Polymyalgia rheumatica (age >50, proximal girdle, no true synovitis, RF-negative)
  • SLE / other CTD arthritis (non-erosive Jaccoud, ANA positive)
  • Gout / CPPD polyarthritis (crystal analysis, tophi)
  • Viral arthritis (parvovirus B19, hepatitis B/C, chikungunya — self-limiting, RF can be transiently positive)
  • Osteoarthritis (DIP/first CMC, bony Heberden/Bouchard nodes, no inflammation)

Investigations

  • RF and anti-CCP (anti-CCP more specific, prognostic for erosive disease)
  • ESR + CRP (disease activity; part of DAS28)
  • FBC, U&E, LFTs (baseline before DMARDs + ongoing monitoring)
  • X-rays hands/feet (periarticular osteopenia, erosions, joint space loss) — baseline + progression
  • ANA (overlap/mimic screen), hepatitis B/C + HIV serology (before immunosuppression)
  • Baseline CXR and consider quantiferon/TB screen before biologics; HBV reactivation risk
  • Ultrasound/MRI for subclinical synovitis if diagnosis uncertain

Management

  • Confirm diagnosis (2010 ACR/EULAR classification: joints involved + serology + acute phase + duration) and assess disease activity (DAS28/CDAI)
  • Start csDMARD monotherapy as soon as diagnosis made — methotrexate first-line unless contraindicated; prescribe folic acid alongside
  • Add short-term bridging glucocorticoid (oral taper or IM/IA depot) to control symptoms while DMARD takes effect (6-12 weeks); keep steroid course as short as possible
  • Treat-to-target: review at 1-3 months; if target (remission/LDA) not reached by 3-6 months, escalate — step up csDMARD combination or add bDMARD/tsDMARD
  • If poor prognostic factors (high activity, erosions, high-titre RF/anti-CCP) and csDMARD failure: add biologic (TNF inhibitor usual first) or JAK inhibitor
  • JAK inhibitor: use with caution and prefer a biologic if age >=65, smoker, prior MACE/VTE or malignancy risk (ORAL Surveillance signal)
  • Monitor DMARD toxicity on schedule (FBC/LFT/U&E), vaccinate (pneumococcal, annual influenza, avoid live vaccines on biologics), manage CV risk and osteoporosis
  • Counsel on pregnancy planning: stop methotrexate + leflunomide (teratogenic) pre-conception; hydroxychloroquine, sulfasalazine, azathioprine, certolizumab are pregnancy-compatible

Drugs & doses

Methotrexate 15 mg ORALLY once weekly start; titrate to 20-25 mg/week over 6-8 weeks (oral or SC if GI intolerance/poor response); NEVER daily dosing — fatal toxicity [verify local dose]
Folic acid 5 mg ORALLY once weekly on a different day from methotrexate (UK practice; some give 5 mg daily except MTX day) to reduce mucositis/cytopenia/LFT derangement
Sulfasalazine 500 mg ORALLY daily, increase weekly to 1 g twice daily (alternative/combination csDMARD; pregnancy-safe)
Hydroxychloroquine 200-400 mg ORALLY daily (max 5 mg/kg actual body weight/day — retinopathy risk; baseline + annual eye screen)
Leflunomide 10-20 mg ORALLY once daily (alternative csDMARD; teratogenic — washout with cholestyramine if conception/toxicity)
Prednisolone 15-30 mg ORALLY daily short tapering bridge, or methylprednisolone 80-120 mg IM, or intra-articular triamcinolone for flare [verify local dose]
TNF inhibitor e.g. adalimumab 40 mg SC every 2 weeks, or etanercept 50 mg SC weekly (after csDMARD failure; screen TB/HBV first) [verify local]
Alternative biologics: tocilizumab (IL-6R), abatacept (T-cell co-stim), rituximab 1 g IV x2 (seropositive/refractory) [verify local]
JAK inhibitor e.g. baricitinib 4 mg or tofacitinib 5 mg ORALLY twice daily — only after weighing MACE/VTE/malignancy risk [verify local]
NSAID e.g. naproxen 250-500 mg ORALLY twice daily with PPI cover for symptom relief (not disease-modifying)

Disposition

Outpatient rheumatology — urgent referral for suspected new RA (treat within weeks of symptom onset). ED role: start bridging analgesia/steroid, arrange early clinic, exclude septic joint. Admit only for systemic complications (vasculitis, severe ILD, sepsis, cervical myelopathy).

Complications & pitfalls

  • Joint destruction, deformity and disability
  • RA-interstitial lung disease, pleuritis, rheumatoid nodules
  • Accelerated atherosclerosis — leading cause of excess mortality
  • Cervical spine (atlanto-axial) instability
  • Felty syndrome (RA + splenomegaly + neutropenia), secondary Sjogren, amyloidosis
  • Increased lymphoma risk; infection risk from immunosuppression

Exam pearls

  • Treat-to-target with early methotrexate is the backbone of both ACR 2021 and EULAR 2022/2023 recommendations — do not delay DMARD waiting for specialist if diagnosis clear.
  • ACR 2021: methotrexate monotherapy strongly preferred first-line even in moderate-high activity; EULAR: MTX + short glucocorticoid bridge.
  • EULAR 2022/2023: bDMARD preferred over JAK inhibitor if risk factors for malignancy/MACE/VTE (post ORAL Surveillance).
  • Always flag cervical spine (atlanto-axial subluxation) before any intubation/general anaesthetic in long-standing RA.
  • Folic acid is mandatory co-prescription with methotrexate; check FBC/LFT/U&E per local shared-care protocol.
  • A single acutely hot joint in RA is septic arthritis until proven otherwise — aspirate, do not just uptitrate steroid. [verify local]

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.